1527-3350/asset/cover.gif?v=1&s=3cd983af6575c8dbfd6b47a63ffa95415ace15f8 "Hepatology")
fax: +49 511 220027186
1527-3350/asset/olbannerleft.gif?v=1&s=4b2409f9534ed500d3c8da1940a23842e2b9932d)
1527-3350/asset/olbannerright.gif?v=1&s=141b9a8485298533c3e2016e937b0404f7d933e1)
Viral Hepatitis
You have full text access to this OnlineOpen article
The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry†‡
Article first published online: 30 NOV 2011
DOI: 10.1002/hep.24610
Copyright © 2011 American Association for the Study of Liver Diseases
Additional Information
How to Cite
Ciesek, S., von Hahn, T., Colpitts, C. C., Schang, L. M., Friesland, M., Steinmann, J., Manns, M. P., Ott, M., Wedemeyer, H., Meuleman, P., Pietschmann, T. and Steinmann, E. (2011), The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology, 54: 1947–1955. doi: 10.1002/hep.24610
- †
Potential conflict of interest: Dr. Schang is a consultant for Epiphany Biosciences.
- ‡
This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG) (HA 4393/2-1; to T.V.H.) and (Ci 171/2-1; to S.C.) and from the CIHR and BWF (to L.M.S.). T.P. was supported by grants from the Helmholtz Association SO-024 and the DFG (PI 734/2-1 and SFB 900, Teilprojekt A6). E.S. was supported by an intramural young investigator award of the Helmholtz Center for Infection Research and the DFG (STE 1954/1-1). C.C.C. was supported by the NSERC and AHFMR.
- §
fax: +49 511 220027186
Publication History
- Issue published online: 30 NOV 2011
- Article first published online: 30 NOV 2011
- Accepted manuscript online: 11 AUG 2011 09:27AM EST
- Manuscript Accepted: 1 AUG 2011
- Manuscript Received: 20 JUN 2011
References
- 1, , . Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
- 2, . Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol 2011; 8: 69-71.
- 3, , . Retransplantation in patients with hepatitis C recurrence after liver transplantation. J Hepatol 2010; 53: 962-970.
- 4, , , , , , et al. Glucocorticosteroids increase cell entry by hepatitis C virus. Gastroenterology 2010; 138: 1875-1884.
- 5, , , , , , et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796.
- 6, , , , , , et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626.
- 7, , , , , , et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 2005; 102: 9294-9299.
- 8, , , , , , et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA 2006; 103: 7408-7413.
- 9, , . New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci 2011; 102: 317-323.
- 10, , , , . Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Res 2002; 53: 19-34.
- 11, , , . Inhibition of adenovirus infection and adenain by green tea catechins. Antiviral Res 2003; 58: 167-173.
- 12, , . Antiviral effect of catechins in green tea on influenza virus. Antiviral Res 2005; 68: 66-74.
- 13, , , , , , et al. Epigallocatechin gallate inactivates clinical isolates of herpes simplex virus. Antimicrob Agents Chemother 2008; 52: 962-970.
- 14, , , , . Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication-inducible cell line. World J Gastroenterol 2011; 17: 1507-1514.
- 15, , , , , , et al. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. HEPATOLOGY 2009; 49: 364-377.
- 16, , , , , , . Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol 2006; 80: 5308-5320.
- 17, , , , , , et al. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol 2010; 84: 5751-5763.
- 18, , , , , , et al. Impact of occludin intra- and interspecies variation on its coreceptor function for authentic hepatitis C virus particles. J Virol 2011; 85: 7613-7621.
- 19, , , , , , et al. Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol 2010; 28: 167-171.
- 20, , , , , , et al. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog 2010; 6: e1001086.
- 21, , , , , . Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem 2006; 281: 25177-25183.
- 22, , , , , , . Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. HEPATOLOGY 2006; 43: 932-942.
- 23, , , . Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol 2011; 54: 566-576.
- 24, , , , , , et al. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol 2011; 54: 48-55.
- 25, , , , , , et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17: 589-595.
- 26, , , , , , et al. Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses. Proc Natl Acad Sci USA 2010; 107: 17339-17344.
- 27, , , , , , et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003; 9: 3312-3319.
- 28, , , . Activity of compounds from Chinese herbal medicine Rhodiola kirilowii (Regel) Maxim against HCV NS3 serine protease. Antiviral Res 2007; 76: 86-92.